DSE/PHARMAID (DSE/PHARMAID)

Dhaka Stock Exchange: DSE/PHARMAID · BDT

BDT 545

-1.50 (-0.3%)· Recorded snapshot

Market cap	1.7B
Revenue (ttm)	495.7M
Net income (ttm)	77.6M
EPS (ttm)	BDT 24.9
Shares out	3.1M
P/E (trailing)	21.9x
Dividend	BDT 3.00 (0.55%)
Volume	5,004
Beta	0.18

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 495.7M
Net income (ttm): 77.6M
EPS (ttm): BDT 24.9
P/E (trailing): 21.9x
Market cap: 1.7B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E21.9

P25 n/aP50 n/aP75 n/a

ROE17.2

P25 n/aP50 n/aP75 n/a

ROIC17.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All DSE/PHARMAID indicators

Market & fundamental data

Available fields

241

Groups with data

Currency

BDT

Showing 241 of 241 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	BDT
Country	Bangladesh
Country code	BD
Earnings date	2026-11-04
Employees	94
Employees change	8
Employees growth	9.3%
Enterprise value	BDT 1.7B
Exchange	Dhaka Stock Exchange
Financial currency	BDT
Financial report date	2026-03-31
First seen	2026-05-10
Fiscal year end	June
Founded	1981
Industry	Pharmaceutical Preparations
Is primary listing	Yes
ISIN number	BD0462PHAID7
Last earnings date	2026-04-29
Last refreshed	2026-10-29
Last stock split date	2011-12-04
Last stock split type	Forward
Market cap	BDT 1.7B
Next earnings date	2026-11-04
Price	BDT 544.60
Price currency	BDT
SIC code	2834
Stock price date	2026-10-29
Symbol	dse/PHARMAID
Website	https://www.pharmaaids.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	47.9x
Average P/E ratio (3Y)	36.34x
Average P/E ratio (5Y)	67.28x
Earnings yield	4.57%
EV/Earnings	21.66x
EV/EBIT	16.16x
EV/EBITDA	14.81x
EV/FCF	249.66x
EV/Sales	3.39x
FCF / EV yield	0.4%
FCF yield	0.4%
Graham number	295.13053
Graham upside	-45.96%
Industry P/E	9.79x
Lynch fair value	BDT 276.95
Lynch upside	-49.29%
P/B ratio	3.51x
P/E ratio	21.88x
P/FCF ratio	252.91x
P/OCF ratio	27.08x
P/S ratio	3.44x
Price / tangible book value	3.51x
Price/EBITDA ratio	15x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	21%
EBITDA margin	22.92%
Effective tax rate	23.7%
FCF margin	1.36%
Gross margin	31.4%
Operating margin	21%
Pretax margin	20.53%
Profit margin	15.66%
Profit per employee	BDT 826,020
Revenue per employee	BDT 5.3M
ROA	10.57%
ROA (5Y)	9.15%
ROCE	21.3%
ROE	17.19%
ROE (5Y)	12.75%
ROIC	17.52%
ROIC (5Y)	13.32%
Tax / revenue	4.87%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	46.27%
EPS growth (Q)	37.32%
EPS growth (QoQ)	-16%
EPS growth 10Y	13.1%
EPS growth 5Y	11.13%
FCF growth (Q)	624.4%
FCF growth (QoQ)	130.23%
FCF growth 5Y	-22.6%
Gross profit growth	28.95%
Gross profit growth (Q)	29.69%
Gross profit growth 3Y	44.71%
Gross profit growth 5Y	9.48%
Net income growth	46.27%
Net income growth (Q)	37.32%
Net income growth (QoQ)	-16%
Net income growth 5Y	11.13%
OCF growth	27,438.32%
OCF growth (Q)	340.08%
OCF growth (QoQ)	133.16%
OCF growth 10Y	78.92%
OCF growth 3Y	172.47%
OCF growth 5Y	12.75%
Operating income growth	39.87%
Operating income growth (Q)	42.68%
Operating income growth 3Y	474.51%
Operating income growth 5Y	10.94%
Revenue growth	18.93%
Revenue growth (Q)	20.79%
Revenue growth (QoQ)	-13.37%
Revenue growth 10Y	13.56%
Revenue growth 3Y	17.99%
Revenue growth 5Y	12.78%

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	BDT -56.2M
Depreciation and amortization	BDT 9.5M
EBIT	BDT 104.1M
EBITDA	BDT 113.6M
EPS	BDT 24.89
FCF per share	BDT 2.16
Financing cash flow	BDT -10M
Free cash flow	BDT 6.7M
Gross profit	BDT 155.7M
Income taxes	BDT 24.1M
Investing cash flow	BDT -56.7M
Net borrowing	BDT -325,993
Net cash flow	BDT -3.8M
Net income	BDT 77.6M
Operating income	BDT 104.1M
Revenue	BDT 495.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	9.17
Book value per share	BDT 155.55
Debt / EBITDA	0.15
Debt / equity	0.04
Debt / FCF	2.56
Interest coverage	42.65
Long-term assets	BDT 140.3M
Long-term liabilities	BDT 3.4M
Net cash (debt)	BDT 21.9M
Net cash / market cap	1.28%
Net cash growth	10.72%
Net debt / EBITDA	-0.19
Net debt / equity	-0.05
Net debt / FCF	-3.25
Piotroski F-Score	6
Property, plant and equipment	BDT 140.3M
Shareholders' equity	BDT 485.3M
Tangible book value	BDT 485.3M
Tangible book value per share	BDT 155.55
Total assets	BDT 647.2M
Total cash	BDT 39.2M
Total debt	BDT 17.3M
Total liabilities	BDT 161.9M
WACC	5.3%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.81
Current assets	BDT 506.9M
Current liabilities	BDT 158.5M
Current ratio	3.2
Inventory turnover	4.73
Net working capital	BDT 326.6M
Quick ratio	1.47
Working capital	BDT 348.5M
Working capital turnover	1.47

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend growth	20%
Dividend growth (10Y)	1.84%
Dividend growth (3Y)	-15.66%
Dividend growth (5Y)	-9.71%
Dividend growth years	2
Dividend payment date	2026-01-25
Dividend payment years	18
Dividend payout frequency	Annual
Dividend per share	BDT 3.00
Dividend yield	0.55%
Ex-dividend date	2025-12-08
FCF payout ratio	138.94%
Last dividend	BDT 3.00
Payout ratio	12.49%
Shareholder yield	0.55%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	115.77%
10Y return CAGR	8.86%
10Y total return	133.59%
150-day SMA	BDT 571.57
15Y price change	205%
15Y return CAGR	8.62%
15Y total return	245.84%
1D price change	-0.27%
1M price change	-1.76%
1M total return	-1.76%
1W price change	1.7%
1W total return	1.7%
1Y price change	6.58%
1Y return CAGR	7.2%
1Y total return	7.2%
20-day SMA	BDT 552.56
200-day SMA	BDT 560.89
20Y price change	5,397.84%
20Y return CAGR	23.42%
20Y total return	6,619.54%
3M price change	-11.35%
3M total return	-11.35%
3Y price change	-30.93%
3Y return CAGR	-11.27%
3Y total return	-30.15%
50-day SMA	BDT 563.08
50-day SMA vs 200-day SMA	50over200
52-week high	BDT 680.00
52-week high date	2026-07-16
52-week low	BDT 452.70
52-week low date	2025-11-13
5Y price change	4.36%
5Y return CAGR	1.41%
5Y total return	7.25%
6M price change	-0.38%
6M total return	-0.38%
All-time high	BDT 980.00
All-time high date	2022-08-28
All-time low	BDT 0.70
All-time low date	1997-06-09
Average true range (ATR)	BDT 15.30
Average volume	9.3K
Beta (1Y)	-0.26
Beta (2Y)	-0.24
Beta (5Y)	0.18
Change from 52-week high	-19.91%
Change from 52-week low	20.3%
Change from all-time high	-44.28%
Change from all-time low	77,958.89%
Dollar volume	BDT 2.7M
High price	BDT 547.20
Low price	BDT 540.00
Monthly RSI	45.08
Position in 52-week range	63.89%
Previous close	BDT 546.10
Price vs 150-day SMA	-4.46%
Price vs 20-day SMA	-1.17%
Price vs 200-day SMA	-2.64%
Price vs 50-day SMA	-3.01%
Relative volume	0.54
RSI	45.07
Sharpe ratio	-0.22
Sharpe ratio (3Y)	-0.34
Sharpe ratio (5Y)	0.24
Sortino ratio	-0.14
Sortino ratio (3Y)	-0.33
Sortino ratio (5Y)	0.57
Volume	5K
Weekly RSI	99.93
YTD price change	12.81%
YTD total return	12.81%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2.5M
Shares change (QoQ)	0%
Shares held by insiders	18.78%
Shares outstanding	3.1M

Deeper analysis on DSE/PHARMAID

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this DSE/PHARMAID report

Is a complete DSE/PHARMAID research report available?

No complete published report is available for dse/PHARMAID (DSE/PHARMAID) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

DSE/PHARMAID (DSE/PHARMAID)

Price

Financial snapshot

Fair-value bridge

Latest news · DSE/PHARMAID

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DSE/PHARMAID indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DSE/PHARMAID

Frequently asked questions